Influence of characteristics of epicardial adipose tissue and myocardial sympathetic innervation on the development of late recurrence of atrial fibrillation after radiofrequency ablation

Aim. To investigate the relationship between radiological characteristics of epicardial adipose tissue (EAT) and myocardial sympathetic activity, as well as to study their association with late recurrence of atrial fibrillation (AF) after radiofrequency ablation (RFA).

Material and methods. This prospective study included 26 people with persistent and long-standing persistent AF scheduled for interventional AF treatment. Before the RFA procedure, all patients underwent cardiac 123I-metaiodobenzylguanidine (123I-MIBG) scintigraphy to assess the myocardial sympathetic innervation and contrast-enhanced cardiac multislice computed tomography to assess pulmonary vein anatomy, left atrial volume, and EAT volume. Clinical follow-up, including 12-lead electrocardiography (ECG) and 24-hour ECG monitoring, was carried out 3, 6 and 12 months after RFA.

Results. After the end of follow-up, the patients were divided into two groups: with AF recurrence (group 1, n=8) and without AF recurrence (group 2, n=18). Multivariate logistic analysis found that only the 123I-MIBG washout rate (odds ratio, 1,0943; 95% confidence interval, 1,0138-1,1812) proved to be an independent predictor of late AF recurrence after RFA. ROC analysis revealed that a 123I-MIBG washout rate >21% with a sensitivity of 75% and a specificity of 83,3% (AUC=0,844; p<0,001) predicts late AF recurrence after RFA.

Conclusion. Parameters of myocardial sympathetic activity, assessed by 123I-MIBG myocardial scintigraphy, are associated with late AF recurrence after RFA in patients with persistent and long-standing persistent AF. There were no reliable data confirming associations between myocardial sympathetic innervation and radiological EAT indicators, as well as the effect of the latter on the risk of AF recurrence after RFA.

1. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2020;ehaa612. doi:10.1093/eurheartj/ehaa612. Online ahead of print.

2. Kirchhof P, Calkins H. Catheter ablation in patients with persistent atrial fibrillation. Eur Heart J. 2017;38(1):20-6. doi:10.1093/eurheartj/ehw260.

3. Fabritz L, Guasch E, Antoniades C, et al. Expert consensus document: Defining the major health modifiers causing atrial fibrillation: a roadmap to underpin personalized prevention and treatment. Nat Rev Cardiol. 2016;13(4):230-7.

4. Teresińska A. I-123-MIBG cardiac innervation imaging in patients with atrial fibrillation. J Nucl Cardiol. 2020;27(6):1951-4. doi:10.1007/s12350-019-01601-6.

5. Akutsu Y, Kaneko K, Kodama Y, et al. Iodine-123 mIBG Imaging for Predicting the Development of Atrial Fibrillation. JACC Cardiovasc Imaging. 2011;4(1):78-86. doi:10.1016/j.jcmg.2010.10.005.

6. Arimoto T, Tada H, Igarashi M, et al. High washout rate of iodine-123- metaiodobenzylguanidine imaging predicts the outcome of catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol. 2011;22(12):1297-304. doi:10.1111/j.1540-8167.2011.02123.x.

7. Kawasaki M, Yamada T, Furukawa Y, et al. Are cardiac sympathetic nerve activity and epicardial adipose tissue associated with atrial fibrillation recurrence after catheter ablation in patients without heart failure? Int J Cardiol. 2020;303:41-8. doi:10.1016/j.ijcard.2019.11.092.

8. Wenning C, Lange PS, Schülke C, et al. Pulmonary vein isolation in patients with paroxysmal atrial fibrillation is associated with regional cardiac sympathetic denervation. EJNMMI Res. 2013;3(1):81. doi:10.1186/2191-219X-3-81.

9. Flotats A, Carrio I, Agostini D, et al. Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur J Nucl Med Mol Imaging. 2010;37:1802-12. doi:10.1007/s00259-010-1491-4.

10. Thanassoulis G, Massaro JM, O’Donnell CJ, et al. Pericardial fat is associated with prevalent atrial fibrillation: The framingham heart study. Circulation. Arrhythmia and electrophysiology. 2010;3:345-50. doi:10.1161/CIRCEP.109.912055.

11. Shamloo AS, Dagres N, Arya A, Hindricks G. Atrial fibrillation: A review of modifiable risk factors and preventive strategies. Rom J Intern Med. 2019;57(2):99-109. doi:10.2478/rjim-2018-0045.

12. Lishmanov YuB, Saushkina YuV, Minin SM, et al. Scintigraphic estimation of the sympathetic innervation of the heart and myocardial perfusion in patients with atrial fibrillation. Russ J Cardiol. 2014;(12):13-8. (In Russ.) doi:10.15829/1560-4071-2014-12-13-18.

13. Abbara S, Arbab-Zadeh A, Callister TQ, et al. SCCT guidelines for performance of coronary computed tomographic angiography: a report of the Society of Cardiovascular Computed Tomography Guidelines Committee. J Cardiovasc Comput Tomogr. 2009;3(3):190-204. doi:10.1016/j.jcct.2009.03.004.

14. Calkins H, Kuck KH, Cappato R, et al. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and Follow-up, Definitions, Endpoints, and Research Trial Design. Europace. 2012;14(4):528-606. doi:10.1093/europace/eus027.

15. Schauerte P, Scherlag BJ, Pitha J, et al. Catheter ablation of cardiac autonomic nerves for prevention of vagal atrial fibrillation. Circulation. 2000;102(22):2774-80. doi:10.1161/01.cir.102.22.2774.